CN105377850A - 抗焦虑化合物的结晶形式 - Google Patents

抗焦虑化合物的结晶形式 Download PDF

Info

Publication number
CN105377850A
CN105377850A CN201380076497.9A CN201380076497A CN105377850A CN 105377850 A CN105377850 A CN 105377850A CN 201380076497 A CN201380076497 A CN 201380076497A CN 105377850 A CN105377850 A CN 105377850A
Authority
CN
China
Prior art keywords
disease
crystalline form
disorder
certain embodiments
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380076497.9A
Other languages
English (en)
Chinese (zh)
Inventor
B·L·弗林
达拉姆·保罗
A·J·哈维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionomics Ltd
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Priority to CN201711041313.1A priority Critical patent/CN107814799A/zh
Publication of CN105377850A publication Critical patent/CN105377850A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380076497.9A 2013-03-15 2013-05-14 抗焦虑化合物的结晶形式 Pending CN105377850A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711041313.1A CN107814799A (zh) 2013-03-15 2013-07-12 抗焦虑化合物的结晶形式

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361787436P 2013-03-15 2013-03-15
US61/787,436 2013-03-15
AU2013204159A AU2013204159B2 (en) 2013-03-15 2013-04-12 A Crystalline Form of an Anxiolytic Compound
AU2013204159 2013-04-12
PCT/AU2013/000497 WO2014138772A1 (en) 2013-03-15 2013-05-14 A crystalline form of an anxiolytic compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711041313.1A Division CN107814799A (zh) 2013-03-15 2013-07-12 抗焦虑化合物的结晶形式

Publications (1)

Publication Number Publication Date
CN105377850A true CN105377850A (zh) 2016-03-02

Family

ID=51628585

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380076497.9A Pending CN105377850A (zh) 2013-03-15 2013-05-14 抗焦虑化合物的结晶形式
CN201711041313.1A Pending CN107814799A (zh) 2013-03-15 2013-07-12 抗焦虑化合物的结晶形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711041313.1A Pending CN107814799A (zh) 2013-03-15 2013-07-12 抗焦虑化合物的结晶形式

Country Status (9)

Country Link
US (2) US9758516B2 (https=)
EP (1) EP2970290B1 (https=)
JP (2) JP2016510767A (https=)
CN (2) CN105377850A (https=)
AU (2) AU2013204159B2 (https=)
CA (1) CA2905573C (https=)
MX (1) MX369451B (https=)
NZ (1) NZ712341A (https=)
WO (1) WO2014138772A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114585362A (zh) * 2019-09-23 2022-06-03 生态有限公司 治疗制剂及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105492440A (zh) * 2013-03-15 2016-04-13 生态学有限公司 抗焦虑化合物的盐、共晶体和多晶型物
WO2018102885A1 (en) * 2016-12-09 2018-06-14 Bionomics Limited Modulators of nicotinic acetylcholine receptors and uses thereof
WO2019109150A1 (en) * 2017-12-07 2019-06-13 Bionomics Limited Methods of treating agitation
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
AU2023201463A1 (en) * 2023-03-08 2024-09-26 Bionomics Limited Method of treating social anxiety disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046135A1 (en) * 2006-10-16 2008-04-24 Bionomics Limited Novel anxiolytic compounds
WO2012116410A1 (en) * 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
WO2012151640A1 (en) * 2011-05-12 2012-11-15 Bionomics Limited Methods for preparing naphthyridines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
KR20070009726A (ko) * 2004-05-07 2007-01-18 테바 파마슈티컬 인더스트리즈 리미티드 나테글리나이드의 다형태

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046135A1 (en) * 2006-10-16 2008-04-24 Bionomics Limited Novel anxiolytic compounds
WO2012116410A1 (en) * 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
WO2012151640A1 (en) * 2011-05-12 2012-11-15 Bionomics Limited Methods for preparing naphthyridines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114585362A (zh) * 2019-09-23 2022-06-03 生态有限公司 治疗制剂及其用途
CN114585362B (zh) * 2019-09-23 2024-05-07 生态有限公司 治疗制剂及其用途

Also Published As

Publication number Publication date
AU2013382559A1 (en) 2015-09-24
CA2905573A1 (en) 2014-09-18
EP2970290A1 (en) 2016-01-20
HK1220187A1 (en) 2017-04-28
US20170305905A1 (en) 2017-10-26
NZ712341A (en) 2019-07-26
MX369451B (es) 2019-11-08
AU2013204159A1 (en) 2014-10-02
CN107814799A (zh) 2018-03-20
AU2013204159B2 (en) 2015-05-07
JP2016510767A (ja) 2016-04-11
CA2905573C (en) 2021-03-02
MX2015013048A (es) 2016-09-07
JP2018109011A (ja) 2018-07-12
US20160039810A1 (en) 2016-02-11
EP2970290B1 (en) 2020-07-22
EP2970290A4 (en) 2016-08-31
WO2014138772A1 (en) 2014-09-18
US9758516B2 (en) 2017-09-12

Similar Documents

Publication Publication Date Title
US10266529B2 (en) Salts, co-crystals, and polymorphs of an anxiolytic compound
US20170305905A1 (en) Crystalline form of an anxiolytic compound
JP2022513959A (ja) 大環状化合物及び疾患の処置におけるそれらの使用
US12152048B2 (en) Nitroxoline prodrug and use thereof
TW200817402A (en) Substituted pteridines
TW200948813A (en) Plk inhibitors
JPWO2020128925A5 (https=)
CN112566894A (zh) D-氨基酸氧化酶(daao)的有效抑制剂及其用途
TW202312994A (zh) 汰癌勝結合物化合物、包含該化合物的醫藥組成物、及其等的使用方法
WO2021071919A1 (en) Hck as a therapeutic target in myd88 mutated diseases
CN114728920B (zh) 一种沃替西汀前药及其应用
US20230011571A1 (en) Small molecule furin inhibitors for treating infectious diseases
WO2024020409A1 (en) Therapeutic compounds, formulations, and use thereof
HK1220187B (en) A crystalline form of an anxiolytic compound
HK40126954A (zh) 募集cereblon的bcl-xl/bcl-2双重降解剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160302

WD01 Invention patent application deemed withdrawn after publication